Molecular Biology of Ovarian Cancer
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Oncology".
Deadline for manuscript submissions: closed (31 December 2020) | Viewed by 2835
Special Issue Editor
Interests: hCG; placenta; reproductive immunology; gynecologic oncology; glycoproteins
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Epithelial ovarian cancer (EOC) represents the most lethal malignancy of the female genital tract. Nowadays, ovarian cancer patients’ prognosis mostly relies on the completeness of surgical tumor resection, clinical staging, and histological tumor grading. Thus, there is a compelling need to identify and validate tumor-specific mechanisms and molecules that are suitable to individualize therapeutic strategies. Interestingly, during EOC evolvement and progression, host anti-tumor immune defence seems to be actively blocked by tumor-derived mediators. By creating this highly suppressive environment, EOC manages to extensively grow and spread in the peritoneal cavity. In addition, recommended therapeutic approaches include beneath primary cytoreductive surgery, a platinum-based chemotherapy with anti-angiogenic agents, or PARP inhibitors. EOC is classified as serous, mucinous, endometrioid, and clear-cell histology, being distinguished in terms of phenotype, molecular background, and aetiology. Research to identify new molecular prognostic markers needs to take this heterogeneity of ovarian cancer into account. A better understanding of the different mechanisms in ovarian cancer subtypes appears crucial to enable new diagnostic and therapeutic approaches.
Prof. Dr. Udo Jeschke
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Epithelial ovarian cancer (EOC)
- Tumor-specific mechanism
- Heterogeneity of ovarian cancer
- Tumor-immune cell micro environment
- New therapeutic strategies in EOC treatment.
